Attention: This website utilizes cookies. If you continue using this website, you accept the usabe of cookies.

More information Accept

am EXECUTIVE CONSULTING

Dr. Axel Müller
Executive Consultant

Associate Partner at

Vice-Chairman of the Supervisory Board

Curriculum Vitae

as of 2014

am EXECUTIVE CONSULTING

Simultaneously as of 2018

Associate Partner at Fidelio Healthcare Partners GmbH & Co. KG, Seefeld

Simultaneously as of 2018

Member of the Supervisory Board at Mutares SE & Co. KGaA, München (since 2019 Vice-Chairman of the Supervisory Board and Chairman of the Audit Comittee)

Simultaneously as of 2020

Member of the Supervisory Board at Mutares Management SE, München

2015 - 2018

Director/Senior Advisor at Arthur D. Little GmbH, Frankfurt

2010 - 2013

Executive board member for production and development of STADA Arzneimittel AG, Bad Vilbel

Collective Executive Board responsibility for the management of an MDAX-listed company with global reach with approx. 2 billion euros in revenue and over 8,000 employees worldwide.

Department responsibility for production, development (incl. regulatory affairs), procurement and supply chain, quality and portfolio management (incl. inlicensing).

Implementation of enterprise-wide “Build the Future” cost efficiency programme including establishment of new corporate governance in operations

Demonstrably highly successful: significant increase in the key financial figures of the STADA Group such as sales +25%, operating profit +34%, EBITDA +29%, net income +32% (H1/2010 vs. H1/2010) as well as share price > +40% (2013, August 6th vs. 2010, September 15th).

1993 - 2010

Exclusive (freelance) consultant of the Executive Board of STADA Arzneimittel AG on corporate strategy and project-related issues, e.g.:

  • Strategic positioning of the company in the individual markets and market segments (1993 – 2010)
  • Design of “STADA – Build the Future” cost efficiency programme (2009 – 2010)
  • Due diligence processes and contract negotiations in the areas of M&A, product acquisitions as well as inlicensing projects (1993 – 2010)
  • Monitoring of healthcare policy trends in Germany and the main EU markets and preparation of aligned position papers (1993 – 2010)

At the same time, gradual assumption of operations management responsibilities in the STADA Group (Vice President since 2005, Senior Vice President since 2008), including:

  • Head of brand business in Germany (STADA GmbH) with approx. 100 million euros revenue in the German OTC market (2009 – 2010)
  • Head of corporate communications including investor relations (2000 – 2010)
  • Country responsibility for Switzerland (1995 – 1999)
  • Project team leader for operational integration of an acquired product package (1995)
  • Head of generics business in Germany (STADApharm GmbH) (1995)
1985 - 1993

Various management positions at STADA Arzneimittel AG, including:

  • Head of Corporate development (1989 – 1993)
  • Head of business segment planning and marketing services (incl. market research and customer service centre) (1988 – 1993)
  • Strategic planning for generics (1987 – 1988)
  • OTC product management (1985 – 1987)
1980 - 1985

Research associate for the Chair of Pharmaceutical Technology at the Institute for Pharmaceutical Sciences at Johannes Gutenberg University of Mainz

1980

Pharmacist licensure

1975 - 1980

Study of pharmaceutical sciences at Johannes Gutenberg University in Mainz

18.06.1957

Born in Koblenz

Top